Journal Mobile Options
Table of Contents
Vol. 55, No. 1, 2009
Issue release date: January 2009

Racial Differences in the Influence of the APOE Epsilon 4 Allele on Cognitive Decline in a Sample of Community-Dwelling Older Adults

Sawyer K. · Sachs-Ericsson N. · Preacher K.J. · Blazer D.G.
To view the fulltext, log in and/or choose pay-per-view option

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Background: Most, but not all, past studies have suggested that the APOE genotype is a risk factor for dementia in whites but not African Americans. This paper first describes explanations as to why some studies may have failed to detect the effect of APOE genotype in African American samples. Briefly, studies have been limited by various methodological problems including small sample sizes, dichotomous measures of cognitive functioning (which tend to be less sensitive to change), and racial bias in assessing demented status. Objective: This paper suggests methods for increasing the likelihood that genuine racial differences will be identified when examining genetic risk factors. Further, we test our model of racial differences in the relationship of APOE genotype and cognitive decline (CD) in a large prospective community sample. Methods: Building on the work of Fillenbaum and colleagues [J Am Geriatr Soc 2001;49:1148–1155], we used data from the Duke EPESE study collected in four waves over a 10-year period (n = 2,076) to illustrate methods which may better assess racial differences in the influence of the APOE ε4 allele on CD. We used multilevel models for repeated measures to examine racial differences in participants’ increase in errors on a continuous measure of cognitive functioning as they aged. Results: We found the APOE ε4 allele to predict CD for both African Americans and whites. Having at least one ε4 allele predicted more cognitive errors at wave 1 and a faster rate of decline for both African Americans and whites over time. While African Americans experienced a faster rate of CD than whites, there was no additional increase in CD from being both African American and a carrier of the ε4 allele. Conclusion: The study points to several common methodological issues that arise when examining racial differences in genetic influences on health-related outcomes. Further, the study’s results highlight the importance of including both African Americans and Caucasians in research concerning the contribution of APOE genotype to CD.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Fillenbaum GG, Landerman LR, Blazer DG, Saunders AM, Harris TB, Launer LJ: The relationship of APOE genotype to cognitive functioning in older African-American and Caucasian community residents. J Am Geriatr Soc 2001;49:1148–1155.
  2. Howieson DB, Camicioli R, Quinn J, Silbert LC, Care B, Moore MM, Dame A, Sexton G, Kaye JA: Natural history of cognitive decline in the old old. Neurology 2003;60:1489–1494.
  3. Petersen RC, Stevens JC, Ganguli M, Tangalos EG, Cummings JL, DeKosky ST: Practice parameter: early detection of dementia: mild cognitive impairment (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001;56:1133–1142.
  4. Busse A, Bischkopf J, Riedel-Heller SG, Angermeyer MC: Mild cognitive impairment: prevalence and incidence according to different diagnostic criteria. Results of the Leipzig Longitudinal Study of the Aged (LEILA75+). Br J Psychiatry 2003;182:449–454.
  5. Lopez OL, Jagust WJ, DeKosky ST, Becker JT, Fitzpatrick A, Dulberg C, Breitner J, Lyketsos C, Jones B, Kawas C, Carlson M, Kuller LH: Prevalence and classification of mild cognitive impairment in the Cardiovascular Health Study Cognition Study. Part 1. Arch Neurol 2003;60:1385–1389.
  6. Lopez OL, Kuller LH, Becker JT, Dulberg C, Sweet RA, Gach HM, DeKosky ST: Incidence of dementia in mild cognitive impairment in the Cardiovascular Health Study Cognition Study. Arch Neurol 2007;64:416–420.
  7. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, Pericak-Vance MA: Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science 1993;261:921–923.
  8. Roses AD: Apolipoprotein E affects the rate of Alzheimer disease expression: beta-amyloid burden is a secondary consequence dependent on APOE genotype and duration of disease. J Neuropathol Exp Neurol 1994;53:429–437.
  9. Strittmatter WJ, Saunders AM, Schmechel DE, Pericak-Vance MA, Enghild J, Salvesen GS, Roses AD: Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci USA 1993;90:1977–1981.
  10. Tang MX, Stern Y, Marder K, Bell K, Gurland B, Lantigua R, Andrews H, Feng L, Tycko B, Mayeux R: The APOE-epsilon4 allele and the risk of Alzheimer disease among African Americans, whites, and Hispanics. JAMA 1998;279:751–755.
  11. Evans DA, Bennett DA, Wilson RS, Bienias JL, Morris MC, Scherr PA, Hebert LE, Aggarwal N, Beckett LA, Joglekar R, Berry-Kravis E, Schneider J: Incidence of Alzheimer disease in a biracial urban community: relation to apolipoprotein E allele status. Arch Neurol 2003;60:185–189.
  12. Tycko B, Lee JH, Ciappa A, Saxena A, Li CM, Feng L, Arriaga A, Stern Y, Lantigua R, Shachter N, Mayeux R: APOE and APOC1 promoter polymorphisms and the risk of Alzheimer disease in African American and Caribbean Hispanic individuals. Arch Neurol 2004;61:1434–1439.
  13. Green RC, Cupples LA, Go R, Benke KS, Edeki T, Griffith PA, Williams M, Hipps Y, Graff-Radford N, Bachman D, Farrer LA; MIRAGE Study Group: Risk of dementia among white and African American relatives of patients with Alzheimer disease. JAMA 2002;287:329–336.
  14. Ioannidis JP, Trikalinos TA, Khoury MJ: Implications of small effect sizes of individual genetic variants on the design and interpretation of genetic association studies of complex diseases. Am J Epidemiol 2006;164:609–614.
  15. Teresi JA, Kleinman M, Ocepek-Welikson K: Modern psychometric methods for detection of differential item functioning: application to cognitive assessment measures. Stat Med 2000;19:1651–1683.
  16. Lee S, Kawachi I, Berkman LF, Grodstein F: Education, other socioeconomic indicators, and cognitive function. Am J Epidemiol 2003;157:712–720.
  17. Fillenbaum G, Heyman A, Williams K, Prosnitz B, Burchett B: Sensitivity and specificity of standardized screens of cognitive impairment and dementia among elderly black and white community residents. J Clin Epidemiol 1990;43:651–660.
  18. Gurland BJ, Wilder DE, Cross PE, Teresi JA, Barrett VW: Screening scales for dementia: toward reconciliation of conflicting cross-cultural findings. Int J Geriatr Psychiatry 1992;7:105–113.

    External Resources

  19. Lyketsos CG, Chen LS, Anthony JC: Cognitive decline in adulthood: an 11.5-year follow-up of the Baltimore Epidemiologic Catchment Area Study. Am J Psychiatry 1999;156:58–65.
  20. Miles TP, Froehlich TE, Bogardus ST, Inouye SK: Dementia and race: are there differences between African Americans and Caucasians? J Am Geriatr Soc 2001;49:477–484.
  21. Demirovic J, Prineas R, Loewenstein D, Bean J, Duara R, Sevush S, Szapocznik J: Prevalence of dementia in three ethnic groups: the South Florida program on aging and health. Ann Epidemiol 2003;13:472–478.
  22. Sachs-Ericsson N, Blazer DG: Racial differences in cognitive decline in a sample of community-dwelling older adults: the mediating role of education and literacy. Am J Geriatr Psychiatry 2005;13:968–975.
  23. Blazer DG, Landerman LR, Hays JC, Grady TA, Havlik R, Corti M: Blood pressure and mortality risk in older people: comparison between African Americans and whites. J Am Geriatr Soc 2001;49:375–381.
  24. Murrell JR, Price B, Lane KA, Baiyewu O, Gureje O, Ogunniyi A, Unverzagt FW, Smith-Gamble V, Gao S, Hendrie HC, Hall KS: Association of apolipoprotein E genotype and Alzheimer disease in African Americans. Arch Neurol 2006;63:431–434.
  25. Graff-Radford NR, Green RC, Go RC, Hutton ML, Edeki T, Bachman D, Adamson JL, Griffith P, Willis FB, Williams M, Hipps Y, Haines JL, Cupples LA, Farrer LA: Association between apolipoprotein E genotype and Alzheimer disease in African American subjects. Arch Neurol 2002;59:594–600.
  26. Perry RT, Collins JS, Harrell LE, Acton RT, Go RC: Investigation of association of 13 polymorphisms in eight genes in southeastern African American Alzheimer disease patients as compared to age-matched controls. Am J Med Genet 2001;105:332–342.
  27. Cornoni-Huntley J, Blazer D, Lafferty M, Everett D, Brock D, Farmer M (eds): Established Populations for Epidemiologic Studies of the Elderly: Resource Data Book. Bethesda, National Institute on Aging, 1990.
  28. Pfeiffer E: A short portable mental status questionnaire for the assessment of organic brain deficit in elderly patients. J Am Geriatr Soc 1975;23:433–441.
  29. Rosow I, Breslau N: A Guttman health scale for the aged. J Gerontol 1966;21:556–559.
  30. Douglas CE: Mortality differences by APOE genotype estimated from demographic synthesis. Genet Epidemiol 2002;22:146–155.
  31. Rasbash J, Steele F, Browne W, Prosser B: A User’s Guide to MLwiN Version 2.0. Bristol, University of Bristol, 2005.
  32. Singer JD, Willett JB: Applied Longitudinal Data Analysis: Modeling Change and Event Occurrence. New York, Oxford University Press, 2003.
  33. DeKosky ST, Marek K: Looking backward to move forward: early detection of neurodegenerative disorders. Science 2003;302:830–834.
  34. Stewart R, Russ C, Richards M, Brayne C, Lovestone S, Mann A: Depression, APOE genotype and subjective memory impairment: a cross-sectional study in an African-Caribbean population. Psychol Med 2001;31:431–440.
  35. Larson EB, Wang L, Bowen JD, McCormick WC, Teri L, Crane P, Kukull W: Exercise is associated with reduced risk for incident dementia among persons 65 years of age and older. Ann Intern Med 2006;144:73–81.
  36. Spangler JG, Konen JC: Predicting exercise and smoking behaviors in diabetic and hypertensive patients. Age, race, sex, and psychological factors. Arch Fam Med 1993;2:149–155.
  37. Lewis TT, Everson-Rose SA, Sternfeld B, Karavolos K, Wesley D, Powell LH: Race, education, and weight change in a biracial sample of women at midlife. Arch Intern Med 2005;165:545–551.
  38. Gary TL, Baptiste-Roberts K, Gregg EW, Williams DE, Beckles GL, Miller EJ 3rd, Engelgau MM: Fruit, vegetable and fat intake in a population-based sample of African Americans. J Natl Med Assoc 2004;96:1599–1605.
  39. Reusser ME, McCarron DA: Reducing hypertensive cardiovascular disease risk of African Americans with diet: focus on the facts. J Nutr 2006;136:1099–1102.
  40. Markides KS, Martin HW: Predicting self-related health among the aged. Res Aging 1979;1:97–112.

    External Resources

  41. Pettit JW, Kline JP, Gencoz T, Gencoz F, Joiner TE: Are happy people healthier? The specific role of positive affect in predicting self-reported health symptoms. J Res Pers 2001;35:521–536.

    External Resources

  42. Pettit T, Livingston G, Manela M, Kitchen G, Katona C, Bowling A: Validation and normative data of health status measures in older people: the Islington Study. Int J Geriatr Psychiatry 2001;16:1061–1070.
  43. Mossey JM, Shapiro E: Self-rated health: a predictor of mortality among the elderly. Am J Public Health 1982;71:800–808.

    External Resources

  44. Fillenbaum GG, Blazer DG, Burchett BM, Saunders AM, Taylor DH Jr: Apolipoprotein E ε4 and risk of mortality in African American and white older community residents. Gerontologist 2002;42:381–386.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50